evaluate novo nordisk on glp-1 agonists receptor and next-generation metabolic hormone therapies in chronic kidney disease Wall Street Underestimates Novo Nordisk's

Aronne, L

Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial

J Clin Invest 2014;124:4223-6.ArticlePubMedPMC 100

These drugs are prescribed not only for type 2 diabetes but increasingly for chronic weight management, particularly in adults with a body mass index indicating obesity or overweight status with related health risks

Long-term conclusions rely on extrapolation Marie Spreckley, obesity researcher and public health nutritionist at the University of Cambridge in England, who was not involved in the study, cautioned that the papers long-term conclusions rely on modeled projections, rather than observed data, as the follow-up period for stopping treatment with newer medicines is limited to about 12 months

Over 40 weeks, orforglipron patients saw their A1C levels drop by 1.3% to 1.6% , depending on the dosage